Method and molecules

Patent metadata

Field	Value
Publication number	US-11759526-B2
Application number	US-201816615582-A
Country	US
Kind code	B2
Filing date	May 25, 2018
Priority date	May 26, 2017
Publication date	Sep 19, 2023
Grant date	Sep 19, 2023

Abstract

The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.

First claim

The invention claimed is:

1. An antibody or binding fragment thereof conjugated to a payload, wherein the conjugation reaction linking the antibody or binding fragment thereof to the payload was via a Diels-Alder reaction between a diene and a dieneophile to form a cyclohexene ring, and wherein the resulting conjugate is represented by formula (IVa):

wherein
R Y represents the payload; and
R Z represents the antibody or binding fragment thereof;

or wherein the resulting conjugate is represented by formula (IVb):

wherein
R Y represents the payload;
R Z represents the antibody or binding fragment thereof, and
X 4 represents —CH 2 —.

2. The antibody or binding fragment thereof conjugated to a payload according to claim 1 , wherein the payload is selected from:
a. an auristatin,
b. a maytansinoid,
c. a toxin, and
d. a polymer.

3. A pharmaceutical composition comprising the antibody or binding fragment thereof conjugated to a payload according to claim 1 and a diluent, carrier and/or excipient.

4. A method of treating a patient comprising administering a therapeutically effective amount of the antibody or binding fragment thereof conjugated to a payload according to claim 1 .

5. A method of treating a patient comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 3 .

Assignees

• Medimmune Llc
• Univ California

Inventors

• Christie Ronald James
• Gao Changshou
• St Amant Andre Henri
• De Alaniz Javier Read

Classifications

• A61K47/6811 Primary

  the drug being a protein or peptide, e.g. transferrin or bleomycin · CPC title

• C07D307/58 Primary

  One oxygen atom, e.g. butenolide · CPC title

• A61K47/6889

  Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment · CPC title

• A61K47/6923

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title